ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2025
Research on TCM Comprehensive Treatment of DKD Based on Pathophysiological Mechanism.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is the predominant etiology of end-stage renal disease (ESRD). Despite rigorous therapeutic interventions aimed at managing hyperglycemia, regulating blood pressure, and employing renin-angiotensin system inhibitors, the incidence of DKD remains high. Recent investigations have indicated a shift in the disease spectrum of DKD accompanied by significant advancements in the development of novel therapeutic options. Nevertheless, in addition to agents such as renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and mineralocorticoid receptor antagonists (MRA), there is currently no optimal strategy in contemporary medicine to effectively mitigate the progression of DKD. The application of TCM in the management of DKD has demonstrated its potential in delaying disease progression and enhancing patient quality of life, thereby playing a crucial role in the prevention and treatment of this condition. Clinical evidence supports its efficacy and safety profile. This article aimed to explore the TCM approach to DKD, focusing on aspects such as etiology, pathogenesis, syndrome differentiation, and comprehensive treatment, while also analyzing the latest research developments in the pathophysiology of DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.